Atea Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent in USD from 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Atea Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to Q3 2025.
  • Atea Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$42M, a 35% decline year-over-year.
  • Atea Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$147M, a 15.5% increase year-over-year.
  • Atea Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$168M, a 23.9% decline from 2023.
  • Atea Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$136M, a 17.3% decline from 2022.
  • Atea Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$116M, a 196% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

Atea Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$147M -$42M -$10.9M -35% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-12
Q2 2025 -$136M -$37.2M +$3.36M +8.29% Apr 1, 2025 Jun 30, 2025 10-Q 2025-11-12
Q1 2025 -$139M -$34.3M +$28.9M +45.7% Jan 1, 2025 Mar 31, 2025 10-Q 2025-11-12
Q4 2024 -$168M -$33.5M +$5.62M +14.4% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-06
Q3 2024 -$174M -$31.2M +$1.99M +6.01% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-12
Q2 2024 -$176M -$40.5M -$12.3M -43.8% Apr 1, 2024 Jun 30, 2024 10-Q 2025-11-12
Q1 2024 -$164M -$63.2M -$27.7M -78.1% Jan 1, 2024 Mar 31, 2024 10-Q 2025-11-12
Q4 2023 -$136M -$39.2M -$4.73M -13.7% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-06
Q3 2023 -$131M -$33.1M -$25.1M -311% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$106M -$28.2M +$3.15M +10.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$109M -$35.5M +$6.61M +15.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$116M -$34.4M -$152M -129% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $35.7M -$8.07M +$20.1M +71.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $15.5M -$31.3M -$32.9M -2136% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 $48.4M -$42.1M -$72.8M -237% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 $121M $117M +$96.5M +467% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-28
Q3 2021 $24.7M -$28.2M -$10.6M -60% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $35.3M $1.54M +$11.5M Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 $23.8M $30.7M +$34.7M Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 -$10.9M $20.7M +$25.3M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$36.3M -$17.6M -$14M -385% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$22.3M -$9.99M -$6.44M -181% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-12
Q1 2020 -$15.8M -$3.99M -$1.8M -81.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-12
Q4 2019 -$14M -$4.66M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 -$3.63M Jul 1, 2019 Sep 30, 2019 10-Q 2020-12-10
Q2 2019 -$3.55M Apr 1, 2019 Jun 30, 2019 10-Q 2020-12-10
Q1 2019 -$2.19M Jan 1, 2019 Mar 31, 2019 10-Q 2020-12-10

Atea Pharmaceuticals, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$168M -$32.4M -23.9% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-06
2023 -$136M -$20M -17.3% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-06
2022 -$116M -$237M -196% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 $121M +$132M Jan 1, 2021 Dec 31, 2021 10-K 2023-02-28
2020 -$10.9M +$3.09M +22% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 -$14M -$4.97M -54.8% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 -$9.06M Jan 1, 2018 Dec 31, 2018 10-K 2021-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.